Original Article
Association of HTRA1 Mutations and Familial Ischemic Cerebral Small-Vessel Disease
N Engl J Med 2009; 360:1729-1739April 23, 2009
- Abstract
Background
The genetic cause of cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL), which is characterized by ischemic, nonhypertensive, cerebral small-vessel disease with associated alopecia and spondylosis, is unclear.
Methods
In five families with CARASIL, we carried out linkage analysis, fine mapping of the region implicated in the disease, and sequence analysis of a candidate gene. We also conducted functional analysis of wild-type and mutant gene products and measured the signaling by members of the transforming growth factor β (TGF-β) family and gene and protein expression in the small arteries in the cerebrum of two patients with CARASIL.
Results
We found linkage of the disease to the 2.4-Mb region on chromosome 10q, which contains the HtrA serine protease 1 (HTRA1) gene. HTRA1 is a serine protease that represses signaling by TGF-β family members. Sequence analysis revealed two nonsense mutations and two missense mutations in HTRA1. The missense mutations and one of the nonsense mutations resulted in protein products that had comparatively low levels of protease activity and did not repress signaling by the TGF-β family. The other nonsense mutation resulted in the loss of HTRA1 protein by nonsense-mediated decay of messenger RNA. Immunohistochemical analysis of the cerebral small arteries in affected persons showed increased expression of the extra domain–A region of fibronectin and versican in the thickened tunica intima and of TGF-β1 in the tunica media.
Conclusions
CARASIL is associated with mutations in the HTRA1 gene. Our findings indicate a link between repressed inhibition of signaling by the TGF-β family and ischemic cerebral small-vessel disease, alopecia, and spondylosis.
Media in This Article
Figure 1
HTRA1 Mutations in Families with Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL).Figure 2
Functional Consequences of HTRA1 Mutations.Article Activity
- Article
Hypertension is a well-known risk factor for nonhereditary cerebral small-vessel disease.1 Genetic causes have been identified for hereditary cerebral small-vessel diseases — cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy,2 autosomal dominant retinal vasculopathy with cerebral leukodystrophy,3 brain small-vessel disease with hemorrhage,4 and familial cerebral amyloid angiopathy.5 Although arteriopathy in these cerebral small-vessel diseases is well documented, little is known about its genetic basis.
Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) is characterized by nonhypertensive cerebral small-vessel arteriopathy with subcortical infarcts, alopecia, and spondylosis, with an onset in early adulthood.6-8 On neuropathological examination, arteriosclerosis associated with intimal thickening and dense collagen fibers, loss of vascular smooth-muscle cells, and hyaline degeneration of the tunica media has been observed in cerebral small arteries.7-9 These pathological findings resemble those seen in patients with nonhereditary ischemic cerebral small-vessel disease.7-11 We conducted a study to determine whether mutations in HTRA1, a gene encoding HtrA serine protease 1, cause CARASIL.
Methods
Subjects and Genetic Analysis
We enrolled a total of six probands from six consanguineous families of Japanese ancestral origin and some of their family members. The first five families were included in a linkage analysis, and one member of the fifth family and one of the sixth family underwent neuropathological examination. Ancestry was reported by the participant or family members.
We isolated genomic DNA from 11 subjects from five of the families with CARASIL: 5 probands, 3 unaffected siblings, and 3 parents. We performed a genomewide linkage analysis using 763 microsatellite markers (Applied Biosystems). Pairwise lod scores were calculated with the MLINK program of the LINKAGE software package (version 5.2) and the FASTLINK package (version 4.1).12,13 We established five new microsatellite markers — M1236, M1238, M1241, M1260, and M1264 — on the basis of simple-repeat information from the University of California, Santa Cruz, Human Genome Browser. Primer sequences of these markers are summarized in the Supplementary Appendix (available with the full text of this article at NEJM.org). We designed primer pairs for amplification of the nine coding exons of HTRA1.
We isolated genomic DNA from all participants, including healthy persons of Japanese ancestral origin, as determined by means of self-report. These control subjects were between 74 and 90 years of age and had no signs of dementia, as defined by the Mini–Mental State Examination. We obtained fibroblast specimens from four controls and from Subject II-2 in Family 1.
We obtained written informed consent from the affected persons and their family members and written informed consent from the controls. The institutional review board of Niigata University approved this study.
Assay of HTRA1 Protease Activity
To express HTRA1 in Escherichia coli as fusions with glutathione S-transferase, we subcloned wild-type or mutant HTRA1 complementary DNA (cDNA), lacking codons 1 through 140, into the vector pGEX 6P-3 (GE Healthcare). The N-terminus of HTRA1 is toxic to E. coli. Amino acid substitution of the serine protease motif S328A, which abolishes the protease activity in HTRA1, was used as a negative control.14 Glutathione S-transferase fusion proteins were overexpressed and purified. Protease activity, measured as fluorescein isothiocyanate–labeled substrate β-casein, was evaluated with the use of a QuantiCleave Fluorescent Protease Assay Kit (Pierce) and recombinant glutathione S-transferase–HTRA1. To eliminate the possibility that a deletion of the N-terminus in HTRA1 affects protease activity, we also performed the identical protease assay using the serum-free medium containing cells stably expressing full-length wild-type or mutant HTRA1 tagged with a green fluorescent protein at the C-terminus. Green fluorescent protein–tagged HTRA1 proteins were detected by means of anti–green fluorescent protein antibody (Medical and Biological Laboratories, Nagoya, Japan).
To assay the formation of a stable complex with α1-antitrypsin, we transiently expressed α1-antitrypsin and either wild-type or mutated HTRA1 cDNA with a simian virus 5 peptide (V5) tag at the C-terminus in the human embryonic kidney cell line HEK293. These cells were grown in serum-free medium, and samples of the resultant conditioned medium were then immunoblotted with anti–V5 antibody.14
Expression of HTRA1 and NOG
Total RNA was isolated from specimens of whole blood or cultured skin fibroblasts, and cDNA was synthesized with the use of the High-Capacity cDNA Reverse Transcription kit (Applied Biosystems). We assayed the expression of HTRA1 messenger RNA (mRNA) in whole-blood samples by using gene-specific primers for HTRA1. To assay HTRA1 mRNA levels in cultured skin fibroblasts in relation to the expression of glyceraldehyde-3-phosphate dehydrogenase, we performed a real-time quantitative reverse-transcriptase polymerase-chain-reaction (RT-PCR) assay by using specific TaqMan probes and primer sets (Applied Biosystems). We assayed mRNA levels of the noggin gene (NOG) in cultured skin fibroblasts in relation to the levels of β-actin by using real-time quantitative RT-PCR and SYBR Green (Applied Biosystems) (for details, see the Methods section of the Supplementary Appendix).
Assay of Signaling by TGF-β Family Proteins
We used a site-directed mutagenesis system (GeneTailor, Invitrogen) to synthesize cDNA encoding mutant HTRA1 and cDNA encoding a constitutively active TGF-β1 proprotein (pro–TGF-β1 containing the activating amino acid mutations C223S and C225S).15 We then individually subcloned this cDNA into the vector pcDNA DEST-40 (Invitrogen). Constitutively active TGF-β1 was synthesized from pro–TGF-β1 containing the activating mutations C223S and C225S. We isolated cDNA from the SMAD family member 2 gene (SMAD2), obtained from a library of human whole-brain cDNA (Clontech), and subcloned it into the pcDNA DEST-40 vector. Luciferase assays were performed as previously described.16,17 Mouse C2C12 myoblasts (mesenchymal precursor cells, obtained from the American Type Culture Collection) were cotransfected with HTRA1-expression vectors, the pRL-TK renilla luciferase expression plasmid, and the following constructs: the (Smad binding element)4–firefly luciferase vector (TGF-β–responsive reporter vector) and vectors containing SMAD2, the SMAD family member 4 gene (SMAD4), and TGFB1 (encoding pro–TGF-β1 with the two point mutations C223S and C225S)15; the pGL3-Id985WT–firefly luciferase vector (bone morphogenetic protein [BMP]–responsive reporter vector)17 and vectors containing the SMAD family member 1 gene (SMAD1), SMAD4, and BMP-4 (encoding pro–BMP-4); and the pGL3-Id985WT–firefly luciferase vector17 and vectors containing SMAD1, SMAD4, and BMP-2 (encoding pro–BMP-2).18 Cell extracts were assayed for luciferase activity with the use of the Dual-Luciferase Reporter Assay System (Promega). The luciferase activity was corrected for transfection efficiency by dividing it by the pRL-TK renilla luciferase activity. Every sample was transfected in triplicate, and every experiment was repeated three times.
Phosphorylation of SMAD Proteins
HEK293 cells were cotransfected with vectors containing HTRA1 and the following constructs: vectors containing SMAD2, SMAD4, and TGFB1 (encoding pro–TGF-β1 with two point mutations [C223S and C225S]); vectors containing SMAD1, SMAD4, and BMP-4; and vectors containing SMAD1, SMAD4, and BMP-2.15,18 The cells were lysed in radioimmunoprecipitation assay buffer containing phosphatase inhibitor. We performed Western blotting to detect SMAD1, phosphorylated SMAD1, SMAD2, and phosphorylated SMAD2, using the corresponding anti-SMAD antibodies (Cell Signaling): anti-SMAD1, anti–phospho-SMAD1/5/8, anti-SMAD 2/3, and anti–phospho-SMAD2 antibodies.
Immunohistochemical Studies and In Situ Hybridization
We carried out immunoperoxidase staining on formalin-fixed, paraffin-embedded brain specimens obtained from two patients with CARASIL and from four controls (a 40-year-old woman with amyotrophic lateral sclerosis, an 84-year-old woman, a 62-year-old man with a stroke, and a 36-year-old woman with schizophrenia).8,9 The primary antibodies used were those against TGF-β1 (1:50, Santa Cruz), against versican (1:100, Seikagaku), and against the extra domain–A region of fibronectin (1:100, Abcam). The negative control was prepared with the use of nonimmune IgG as the primary antibody. We used cDNA encoding the extra domain–A region of fibronectin (spanning nucleotides 5404 through 5704 of fibronectin isoform 1 [region NM_212482.1]) as a template for digoxigenin-labeled antisense and sense-complementary RNA probes. The sense probe was used as a negative control. We carried out in situ hybridization on the paraffin-embedded sections by using the probes. After the sections had been washed and blocked, they were incubated with alkaline phosphatase–conjugated anti-digoxigenin antibodies, stained with 4-nitroblue tetrazolium chloride–5-bromo-4-chloro-3-indolyl phosphate solution (Roche), and counterstained with fast red.
Results
Subjects
Clinical characteristics of the six probands with CARASIL are listed in Table 1Table 1
Clinical Characteristics of the Six Probands with CARASIL., and the pedigrees are shown in Figure 1AFigure 1 HTRA1 Mutations in Families with Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CARASIL).. The patients in Families 1 through 5 were enrolled initially, and the causative gene for CARASIL was identified. We then enrolled an additional subject with pathologically confirmed CARASIL, in a sixth family, to perform immunohistochemical analysis. On neuropathological examination of this additional subject, arteriosclerosis associated with intimal thickening and dense collagen fibers were observed in cerebral small arteries (Figure 1I).The probands from the first five families had diffuse white-matter lesions on magnetic resonance imaging (MRI), autosomal recessive inheritance, an onset of initial symptoms between the second and fifth decade, and spondylosis or alopecia (Table 1 and Figure 1E through 1H).6-8 Although the affected persons in Family 5 did not have alopecia and cognitive impairment, we enrolled them because they had diffuse white-matter lesions on MRI and spondylosis, and one (a sibling of the proband in this family) had pathological findings identical to those in the patients with CARASIL.8
Genetic Analysis
From genomewide linkage analysis of the five families enrolled, we obtained maximal cumulative pairwise lod scores of 3.97 and 3.59 at D10S587 and D10S1656 (θ=0.0); all patients were homozygous for these loci (Figure 1A). We then performed fine mapping of the region between D10S597 and D10S575 using D10S1483 and five established polymorphic microsatellite markers (M1236, M1238, M1241, M1260, and M1264; see the Supplementary Appendix) (Figure 1A and 1B). All probands were homozygous for the loci between M1238 and D10S1656, suggesting that the causative gene was located within this 2.4-Mb region.
We first selected HTRA1 as a candidate gene (Figure 1B) because it is expressed in the blood vessels, skin, and bone.19 We identified two homozygous nonsense nucleotide mutations: 1108C→T (resulting in a stop codon at position 370; amino acid mutation R370X) in Family 1 and 904C→T (resulting in a stop codon at 302; R302X) in Family 2 (Figure 1C). We also identified two homozygous missense mutations: 889G→A (predicted to result in the amino acid substitution V297M) in Families 3 and 4 and 754G→A (predicted to result in the amino acid substitution A252T) in Family 5. In addition, we observed the homozygous nonsense mutation 904C→T again in the proband of Family 6. The missense mutations V297M and A252T were located in the genic region encoding the serine protease domain (Figure 1C), and the amino acids predicted to be affected were either completely or largely conserved among the HTRA homologues HTRA1 through HTRA4 and among HTRA1 orthologues (Figure 1D). We did not find evidence of such mutations in the 125 controls.
Protease Activity of Mutant HTRA1
The level of protease activity in the mutant HTRA1 encoded by cDNA containing V297M, A252T, or R302X was 21% to 50% of the activity level in wild-type HTRA1. In contrast, HTRA1 encoded by a construct containing the R370X mutation had a protease activity level similar to that in wild-type HTRA1 (Figure 2A and 2BFigure 2
Functional Consequences of HTRA1 Mutations.). HTRA1 attacks the reactive center loop of α1-antitrypsin, instigating the serine protease activity of α1-antitrypsin, which thereby mediates the formation of a covalent complex between the two molecules.14 We did not observe the formation of a stable complex between α1-antitrypsin and mutant HTRA1 encoded by cDNA containing V297M, A252T, or R302X. In contrast, wild-type HTRA1 and HTRA1 encoded by cDNA containing R370X did form stable complexes with α1-antitrypsin (Figure 2C).Nonsense-Mediated Decay
If a premature stop codon is located at least 50 to 55 nucleotides upstream of the exon–exon junction close to the 3′ end, mRNA may become degraded through nonsense-mediated decay.20 Because the location of R370X fulfills this criterion for decay (Figure 1C), we determined whether R370X-containing HTRA1 mRNA is degraded by means of nonsense-mediated decay. The level of HTRA1 mRNA expression in fibroblasts from the patient with the R370X mutation was 6.0% of that in fibroblasts from control subjects, and treatment with cycloheximide, an inhibitor of nonsense-mediated decay, increased this level by a factor of four (Figure 3AFigure 3
Nonsense-Mediated Decay of Mutant HTRA1 Messenger RNA.). We did not detect HTRA1 protein in the culture medium of fibroblasts from the patient carrying the R370X mutation (Subject II-2, Family 1) (Figure 3B). Furthermore, analysis of HTRA1 in leukocytes from a heterozygous carrier of this mutation (Subject II-1, Family 1) showed the presence of wild-type HTRA1 mRNA only (Figure 3C).Mutant HTRA1 and Signaling by TGF-β Homologues
The serine protease activity of HTRA1 is necessary for inhibition of TGF-β family signaling.16 We therefore tested the ability of mutant variants of HTRA1 with missense amino acids (i.e., A252T and V297M) to repress signaling by the TGF-β family members BMP-4 and BMP-2 (Figure 4AFigure 4
Effect of Mutations on Transcription by Members of the Transforming Growth Factor β (TGF-β) Family., and Fig. 1 in the Supplementary Appendix). As expected, neither of the missense-mutated HTRA1 proteins repressed signaling by these molecules. To further investigate the ability of the mutant variants of HTRA1 to repress signaling by the TGF-β family members, we assayed phosphorylation of SMAD in these assays (phosphorylated SMAD is a downstream effector of the TGF-β–family signaling pathway), and observed that none of the mutant HTRA1 proteins repressed the subsequent phosphorylation of SMAD proteins (Figure 4B, and Fig. 2 in the Supplementary Appendix).We next investigated TGF-β signaling in fibroblasts from the subject with CARASIL carrying the R370X mutation and observed that TGF-β signaling in these fibroblasts was more than three times that in fibroblasts from control subjects (Figure 4C). In addition, NOG mRNA, which is induced by TGF-β signaling in fibroblasts, was elevated in the proband (Figure 4D, and Fig. 3 in the Supplementary Appendix).21
Increased TGF-β signaling results in vascular fibrosis, with synthesis of extracellular matrix proteins, including the extra domain–A region of fibronectin and versican.22-24 In the patients with CARASIL who carried the R302X or A252T mutation, the tunica intima showed increased expression of the extra domain–A region of fibronectin (Figure 4E through 4H, and Fig. 4A in the Supplementary Appendix) and versican (Figure 4K, and Fig. 4B in the Supplementary Appendix), as compared with that in control subjects (Figure 4M, 4N, and 4O). The result was confirmed by an in situ hybridization assay that used a probe for the extra domain–A region of fibronectin (Figure 4I and 4J, and Fig. 5 in the Supplementary Appendix). Moreover, in the patients with CARASIL, the tunica media exhibited elevated expression of TGF-β1 (Figure 4L and 4P, and Fig. 4C in the Supplementary Appendix). These results indicate increased TGF-β signaling in the cerebral small arteries in patients with CARASIL.
Discussion
Signaling by members of the TGF-β family is closely associated with vascular angiogenesis and remodeling and has multifaceted roles in vascular endothelial and smooth-muscle cells, depending on the type of cell and extracellular matrix.25,26 Moreover, dysregulation of TGF-β–family signaling results in hereditary vascular disorders.26 Defective TGF-β signaling due to mutations in the TGF-β receptors leads to hereditary hemorrhagic telangiectasia, whereas activation of TGF-β signaling contributes to Marfan's syndrome and associated disorders.26 Our findings extend the spectrum of diseases associated with the dysregulation of TGF-β signaling to include hereditary ischemic cerebral small-vessel disease. In addition, the pathological findings in patients with CARASIL resemble those observed in patients with nonhereditary ischemic cerebral small-vessel disease with hypertension, suggesting that hypertension may increase TGF-β signaling.7-11,27 Thus, TGF-β signaling might underlie the molecular basis of nonhereditary ischemic cerebral small-vessel disease with hypertension.
Dysregulation of the inhibition of signaling by members of the TGF-β family also has been linked to alopecia and spondylosis, the other cardinal clinical features of CARASIL. Transgenic mice overexpressing BMP-4, BMP-2, and TGF-β exhibit hair loss or retardation of the development of hair follicles.28,29 Members of the BMP family are well-known regulators of bone formation, repair, and regeneration.30 Furthermore, overexpression of HTRA1 decreases BMP-2–induced mineralization, whereas reduced expression of HTRA1 accelerates mineralization.31 Although the loss of protease activity by HTRA1 on other substrates may be associated with the pathogenesis of CARASIL, our findings strengthen the hypothesis that increased signaling by the TGF-β family contributes to the pathogenesis of CARASIL.14,31-33 It remains unclear why disinhibition of signaling by TGF-β family members caused by mutant HTRA1 results in narrowly restricted clinical phenotypes. Possible explanations are tissue-specific regulation of signaling by the TGF-β family and tissue-specific expression of HTRA1.14,19,33,34
The molecular basis for regulation of TGF-β1 signaling by HTRA1 remains to be elucidated.16,35,36 TGF-β1 is synthesized as a proprotein (pro–TGF-β1) and is subsequently cleaved into latency-associated protein and mature TGF-β1 by proprotein convertase.26 The mature TGF-β1 is noncovalently bound to the latency-associated protein and is sequestered as a latency-associated protein–TGF-β1 complex in an extracellular matrix.26 The mature TGF-β1 is released from the latency-associated protein–TGF-β1 complex. Therefore, the TGF-β1 signaling is regulated by a balance among maturation, sequestration, and presentation. The elastin microfibril interfacer 1 protein (EMILIN1) inhibits TGF-β1 signaling by preventing the processing of pro–TGF-β1 into mature TGF-β1.37 In our study, the patients with CARASIL had increased expression of mature TGF-β1, suggesting that the HTRA1 may also prevent the processing of pro–TGF-β1 into mature TGF-β1, depending on its protease activity.
A single-nucleotide polymorphism in the promoter region of HTRA1, which is associated with elevated levels of HTRA1 expression, is a genetic risk factor for the neovascular form of age-related macular degeneration.38,39 We did not find macular degeneration in the persons with CARASIL.6-8 Although all our patients were younger than the typical age at the onset of the neovascular form of age-related macular degeneration, the absence of macular degeneration in the patients is consistent with the hypothesis that increased expression of HTRA1 contributes to age-related macular degeneration.6-8,38
Our results indicate that disinhibition of TGF-β–family signaling underlies the molecular basis of CARASIL. They also provide a basis for further investigation of therapeutic strategies for ischemic cerebral small-vessel disease, alopecia, and spondylosis.
Supported in part by grants from the Advanced Brain Science Project and Applied Genomics, the Center for Integrated Brain Medical Science, the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the Japan Society for the Promotion of Science, and Niigata University.
Dr. Fukutake reports receiving lecture fees from Mitsubishi Pharma, Kissei, Sanofi, and Novartis. No other potential conflict of interest relevant to this article was reported.
Dr. Hara and Mr. Shiga contributed equally to this article.
We thank the patients and family members for their participation; M. Tsuchiya, Y. Hazama, Y. Koike, R. Izumita, and M. Nihonmatsu for technical assistance; and Drs. B. Vogelstein (Howard Hughes Medical Institute and Sidney Kimmel Comprehensive Cancer Center), T. Katagiri (Saitama Medical School Research Center for Genomic Medicine), and E. Schwartz (Institut für Biotechnologie, Martin Luther Universität Halle–Wittenberg) for their generous gifts of plasmids.
Source Information
From Niigata University, Niigata (K.H., A.S., H.N., A.M., A.Y., A.K., T.T., M.I., Y.Y., T.Y., T.I., R.K., M.N., O.O.); Kameda Medical Center, Kamogawa City (T.F.); Jichi Medical University, Tochigi (H.K., A.T., I.N.); National Center of Neurology and Psychiatry, Tokyo (K.A.); Nihon University School of Medicine, Tokyo (H.S.); Nagaoka-Nishi Hospital, Nagaoka (M.T.); Kashima Rosai Hospital, Kashima (Y.S.); Kasugai Municipal Hospital, Kasugai (M.H.); Minamikyushu National Hospital, Kagoshima (T.A.); Iida Municipal Hospital, Iida (S.Y.); Shinshu University School of Medicine, Matsumoto (S.I.); and University of Tokyo, Tokyo (S.T.) — all in Japan.
Address reprint requests to Dr. Onodera at the Brain Research Institute, Niigata 951-8585, Japan, or at onodera@bri.niigata-u.ac.jp.
- References
References
1
Chui HC . Subcortical ischemic vascular dementia. Neurol Clin 2007;25:717-740
CrossRef | Web of Science | Medline2
Joutel A ,Corpechot C ,Ducros A , et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996;383:707-710
CrossRef | Web of Science | Medline3
Richards A ,van den Maagdenberg AM ,Jen JC , et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet 2007;39:1068-1070
CrossRef | Web of Science | Medline4
Gould DB ,Phalan FC ,van Mil SE , et al. Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J Med 2006;354:1489-1496
Full Text | Web of Science | Medline5
Revesz T ,Ghiso J ,Lashley T , et al. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol 2003;62:885-898
Web of Science | Medline6
Fukutake T ,Hirayama K . Familial young-adult-onset arteriosclerotic leukoencephalopathy with alopecia and lumbago without arterial hypertension. Eur Neurol 1995;35:69-79
CrossRef | Web of Science | Medline7
Maeda S ,Nakayama H ,Isaka K ,Aihara Y ,Nemoto S . Familial unusual encephalopathy of Binswanger's type without hypertension. Folia Psychiatr Neurol Jpn 1976;30:165-177
Medline8
Yanagawa S ,Ito N ,Arima K ,Ikeda S . Cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy. Neurology 2002;58:817-820
Web of Science | Medline9
Oide T ,Nakayama H ,Yanagawa S ,Ito N ,Ikeda S ,Arima K . Extensive loss of arterial medial smooth muscle cells and mural extracellular matrix in cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). Neuropathology 2008;28:132-142
CrossRef | Web of Science | Medline10
Okeda R ,Murayama S ,Sawabe M ,Kuroiwa T . Pathology of the cerebral artery in Binswanger's disease in the aged: observation by serial sections and morphometry of the cerebral arteries. Neuropathology 2004;24:21-29
CrossRef | Web of Science | Medline11
Tanoi Y ,Okeda R ,Budka H . Binswanger's encephalopathy: serial sections and morphometry of the cerebral arteries. Acta Neuropathol (Berl) 2000;100:347-355
CrossRef | Web of Science | Medline12
Lathrop GM ,Lalouel JM ,Julier C ,Ott J . Strategies for multilocus linkage analysis in humans. Proc Natl Acad Sci U S A 1984;81:3443-3446
CrossRef | Web of Science | Medline13
Cottingham RW Jr ,Idury RM ,Schaffer AA . Faster sequential genetic linkage computations. Am J Hum Genet 1993;53:252-263
Web of Science | Medline14
Hu SI ,Carozza M ,Klein M ,Nantermet P ,Luk D ,Crowl RM . Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem 1998;273:34406-34412
CrossRef | Web of Science | Medline15
Brunner AM ,Marquardt H ,Malacko AR ,Lioubin MN ,Purchio AF . Site-directed mutagenesis of cysteine residues in the pro region of the transforming growth factor β 1 precursor: expression and characterization of mutant proteins. J Biol Chem 1989;264:13660-13664
Web of Science | Medline16
Oka C ,Tsujimoto R ,Kajikawa M , et al. HtrA1 serine protease inhibits signaling mediated by Tgfβ family proteins. Development 2004;131:1041-1053
CrossRef | Web of Science | Medline17
Katagiri T ,Imada M ,Yanai T ,Suda T ,Takahashi N ,Kamijo R . Identification of a BMP-responsive element in Id1, the gene for inhibition of myogenesis. Genes Cells 2002;7:949-960
CrossRef | Web of Science | Medline18
Hillger F ,Herr G ,Rudolph R ,Schwarz E . Biophysical comparison of BMP-2, ProBMP-2, and the free pro-peptide reveals stabilization of the pro-peptide by the mature growth factor. J Biol Chem 2005;280:14974-14980
CrossRef | Web of Science | Medline19
De Luca A ,De Falco M ,Severino A , et al. Distribution of the serine protease HtrA1 in normal human tissues. J Histochem Cytochem 2003;51:1279-1284
CrossRef | Web of Science | Medline20
Kuzmiak HA ,Maquat LE . Applying nonsense-mediated mRNA decay research to the clinic: progress and challenges. Trends Mol Med 2006;12:306-316
CrossRef | Web of Science | Medline21
Gazzerro E ,Gangji V ,Canalis E . Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 1998;102:2106-2114
CrossRef | Web of Science | Medline22
Glukhova MA ,Frid MG ,Shekhonin BV , et al. Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 1989;109:357-366
CrossRef | Web of Science | Medline23
Leask A ,Abraham DJ . TGF-β signaling and the fibrotic response. FASEB J 2004;18:816-827
CrossRef | Web of Science | Medline24
Schonherr E ,Jarvelainen HT ,Sandell LJ ,Wight TN . Effects of platelet-derived growth factor and transforming growth factor-β 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem 1991;266:17640-17647
Web of Science | Medline25
Grainger DJ . Transforming growth factor β and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004;24:399-404
CrossRef | Web of Science | Medline26
ten Dijke P ,Arthur HM . Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007;8:857-869
CrossRef | Web of Science | Medline27
O'Callaghan CJ ,Williams B . Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-β(1). Hypertension 2000;36:319-324
Web of Science | Medline28
Liu X ,Alexander V ,Vijayachandra K ,Bhogte E ,Diamond I ,Glick A . Conditional epidermal expression of TGFβ 1 blocks neonatal lethality but causes a reversible hyperplasia and alopecia. Proc Natl Acad Sci U S A 2001;98:9139-9144
CrossRef | Web of Science | Medline29
Botchkarev VA . Bone morphogenetic proteins and their antagonists in skin and hair follicle biology. J Invest Dermatol 2003;120:36-47
CrossRef | Web of Science | Medline30
Yoon BS ,Lyons KM . Multiple functions of BMPs in chondrogenesis. J Cell Biochem 2004;93:93-103
CrossRef | Web of Science | Medline31
Hadfield KD ,Rock CF ,Inkson CA , et al. HtrA1 inhibits mineral deposition by osteoblasts: requirement for the protease and PDZ domains. J Biol Chem 2008;283:5928-5938
CrossRef | Web of Science | Medline32
Clausen T ,Southan C ,Ehrmann M . The HtrA family of proteases: implications for protein composition and cell fate. Mol Cell 2002;10:443-455
CrossRef | Web of Science | Medline33
Tsuchiya A ,Yano M ,Tocharus J , et al. Expression of mouse HtrA1 serine protease in normal bone and cartilage and its upregulation in joint cartilage damaged by experimental arthritis. Bone 2005;37:323-336
CrossRef | Web of Science | Medline34
Grau S ,Baldi A ,Bussani R , et al. Implications of the serine protease HtrA1 in amyloid precursor protein processing. Proc Natl Acad Sci U S A 2005;102:6021-6026
CrossRef | Web of Science | Medline35
Gilicze A ,Kohalmi B ,Pocza P , et al. HtrA1 is a novel mast cell serine protease of mice and men. Mol Immunol 2007;44:2961-2968
CrossRef | Web of Science | Medline36
Launay S ,Maubert E ,Lebeurrier N , et al. HtrA1-dependent proteolysis of TGF-β controls both neuronal maturation and developmental survival. Cell Death Differ 2008;15:1408-1416
CrossRef | Web of Science | Medline37
Zacchigna L ,Vecchione C ,Notte A , et al. Emilin1 links TGF-β maturation to blood pressure homeostasis. Cell 2006;124:929-942
CrossRef | Web of Science | Medline38
Dewan A ,Liu M ,Hartman S , et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 2006;314:989-992
CrossRef | Web of Science | Medline39
Yang Z ,Camp NJ ,Sun H , et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006;314:992-993
CrossRef | Web of Science | Medline
- Citing Articles (25)
Citing Articles
1
Nitu Singh, Raja R. Kuppili, Kakoli Bose. (2011) The structural basis of mode of activation and functional diversity: A case study with HtrA family of serine proteases. Archives of Biochemistry and Biophysics 516:2, 85-96
CrossRef2
H. S. Markus. (2011) Stroke genetics. Human Molecular Genetics 20:R2, R124-R131
CrossRef3
A. Jones, S. Kumar, N. Zhang, Z. Tong, J.-H. Yang, C. Watt, J. Anderson, Amrita, H. Fillerup, M. McCloskey, L. Luo, Z. Yang, B. Ambati, R. Marc, C. Oka, K. Zhang, Y. Fu. (2011) Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice. Proceedings of the National Academy of Sciences 108:35, 14578-14583
CrossRef4
James F. Meschia, Bradford B. Worrall, Stephen S. Rich. (2011) Genetic susceptibility to ischemic stroke. Nature Reviews Neurology 7:7, 369-378
CrossRef5
J. F. Arboleda-Velasquez, J. Manent, J. H. Lee, S. Tikka, C. Ospina, C. R. Vanderburg, M. P. Frosch, M. Rodriguez-Falcon, J. Villen, S. Gygi, F. Lopera, H. Kalimo, M. A. Moskowitz, C. Ayata, A. Louvi, S. Artavanis-Tsakonas. (2011) PNAS Plus: Hypomorphic Notch 3 alleles link Notch signaling to ischemic cerebral small-vessel disease. Proceedings of the National Academy of Sciences 108:21, E128-E135
CrossRef6
A. Shiga, H. Nozaki, A. Yokoseki, M. Nihonmatsu, H. Kawata, T. Kato, A. Koyama, K. Arima, M. Ikeda, S. Katada, Y. Toyoshima, H. Takahashi, A. Tanaka, I. Nakano, T. Ikeuchi, M. Nishizawa, O. Onodera. (2011) Cerebral small-vessel disease protein HTRA1 controls the amount of TGF- 1 via cleavage of proTGF- 1. Human Molecular Genetics 20:9, 1800-1810
CrossRef7
Margaret M. DeAngelis, Alexandra C. Silveira, Elizabeth A. Carr, Ivana K. Kim. (2011) Genetics of Age-Related Macular Degeneration: Current Concepts, Future Directions. Seminars in Ophthalmology 26:3, 77-93
CrossRef8
S. Alamowitch. (2011) Nouveaux syndromes génétiques responsables de vasculopathie cérébrale. Pratique Neurologique - FMC 2:2, 83-93
CrossRef9
H. Singh, Y. Endo, G. Nie. (2011) Decidual HtrA3 negatively regulates trophoblast invasion during human placentation. Human Reproduction 26:4, 748-757
CrossRef10
Linda Truebestein, Annette Tennstaedt, Timon Mönig, Tobias Krojer, Flavia Canellas, Markus Kaiser, Tim Clausen, Michael Ehrmann. (2011) Substrate-induced remodeling of the active site regulates human HTRA1 activity. Nature Structural & Molecular Biology 18:3, 386-388
CrossRef11
Tim Clausen, Markus Kaiser, Robert Huber, Michael Ehrmann. (2011) HTRA proteases: regulated proteolysis in protein quality control. Nature Reviews Molecular Cell Biology 12:3, 152-162
CrossRef12
James F. Meschia. (2011) New Information on the Genetics of Stroke. Current Neurology and Neuroscience Reports 11:1, 35-41
CrossRef13
Y. Yamamoto, L. Craggs, M. Baumann, H. Kalimo, R. N. Kalaria. (2011) Review: Molecular genetics and pathology of hereditary small vessel diseases of the brain. Neuropathology and Applied Neurobiology 37:1, 94-113
CrossRef14
Satoshi Saito, Akihiko Ozaki, Makio Takahashi, Hidefumi Ito, Sadayuki Matsumoto, Hidekazu Tomimoto. (2011) Clustering of multifocal cerebral infarctions in CADASIL: a case report. Journal of Neurology 258:2, 325-327
CrossRef15
Anne Joutel. (2011) Pathogenesis of CADASIL. BioEssays 33:1, 73-80
CrossRef16
Osamu Onodera. (2011) What is cerebral small vessel disease?. Rinsho Shinkeigaku 51:6, 399-405
CrossRef17
Osamu Onodera. (2011) TGF-β family signaling contributes to human cerebral small vessel disease. Rinsho Shinkeigaku 51:11, 943-944
CrossRef18
E. Bernd Ringelstein, Ilka Kleffner, Ralf Dittrich, Gregor Kuhlenbäumer, Martin A. Ritter. (2010) Hereditary and non-hereditary microangiopathies in the young. An up-date. Journal of the Neurological Sciences 299:1-2, 81-85
CrossRef19
H. Singh, S.-i. Makino, Y. Endo, G. Nie. (2010) Inhibition of HTRA3 stimulates trophoblast invasion during human placental development. Placenta 31:12, 1085-1092
CrossRef20
Melisa Merdanovic, Nicolette Mamant, Michael Meltzer, Simon Poepsel, Alexandra Auckenthaler, Rie Melgaard, Patrick Hauske, Luitgard Nagel-Steger, Anthony R Clarke, Markus Kaiser, Robert Huber, Michael Ehrmann. (2010) Determinants of structural and functional plasticity of a widely conserved protease chaperone complex. Nature Structural & Molecular Biology 17:7, 837-843
CrossRef21
Leonardo Pantoni. (2010) Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. The Lancet Neurology 9:7, 689-701
CrossRef22
Enrico Floßmann. 2010. Molecular Genetics of Ischaemic Stroke. .
CrossRef23
Toshio Fukutake. (2010) CARASIL: Identification of the clinical concept. Rinsho Shinkeigaku 50:11, 849-851
CrossRef24
Kenju Hara. (2010) Molecular mechanism and therapeutic strategy for cerebral small vessel disease. Rinsho Shinkeigaku 50:11, 852-854
CrossRef25
C. Opherk, N. Peters, M. Dichgans. (2009) Vaskulitis und genetisch bedingte Mikroangiopathien. Der Internist 50:11, 1200-1209
CrossRef
